kynurenine has been researched along with Allergic Encephalomyelitis in 11 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 8.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 7.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "Although all PPARs ameliorate experimental autoimmune encephalomyelitis (EAE), recent evidence suggests that PPARα, PPARβ/δ agonists have less pronounced immunomodulatory effects and, along with PGC-1α, are not biomarkers of neuroinflammation in contrast to PPARγ." | 6.61 | Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. ( Fakan, B; Szalardy, L; Vecsei, L, 2019) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 4.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "We biochemically altered the KP at different stages of the disease in experimental allergic encephalomyelitis (EAE) mouse model of MS and at two different enzymatic levels of the KP (IDO-1 (indoleamine 2,3 dioxygenase)) and KMO (kynurenine monooxygenase)." | 3.96 | Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression. ( Brew, BJ; Guillemin, GJ; Lim, CK; Sundaram, G, 2020) |
| " Evidence has suggested that the activation of indoleamine-2,3-dioxygenase (IDO), the rate-limiting enzyme in the kynurenine pathway (KP), plays a crucial role in inflammation-related diseases." | 3.96 | Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice. ( Boeira, SP; Cattelan Souza, L; Giacomeli, R; Jesse, CR; Prigol, M; Silva, MRP; Zarzecki, MS, 2020) |
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 3.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "Although all PPARs ameliorate experimental autoimmune encephalomyelitis (EAE), recent evidence suggests that PPARα, PPARβ/δ agonists have less pronounced immunomodulatory effects and, along with PGC-1α, are not biomarkers of neuroinflammation in contrast to PPARγ." | 2.61 | Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. ( Fakan, B; Szalardy, L; Vecsei, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Jand, Y | 1 |
| Ghahremani, MH | 1 |
| Ghanbari, A | 1 |
| Ejtemaei-Mehr, S | 1 |
| Guillemin, GJ | 3 |
| Ghazi-Khansari, M | 1 |
| Mondanelli, G | 1 |
| Coletti, A | 1 |
| Greco, FA | 1 |
| Pallotta, MT | 1 |
| Orabona, C | 1 |
| Iacono, A | 1 |
| Belladonna, ML | 1 |
| Albini, E | 1 |
| Panfili, E | 1 |
| Fallarino, F | 1 |
| Gargaro, M | 1 |
| Manni, G | 1 |
| Matino, D | 1 |
| Carvalho, A | 1 |
| Cunha, C | 1 |
| Maciel, P | 1 |
| Di Filippo, M | 1 |
| Gaetani, L | 1 |
| Bianchi, R | 1 |
| Vacca, C | 1 |
| Iamandii, IM | 1 |
| Proietti, E | 1 |
| Boscia, F | 1 |
| Annunziato, L | 1 |
| Peppelenbosch, M | 1 |
| Puccetti, P | 1 |
| Calabresi, P | 1 |
| Macchiarulo, A | 1 |
| Santambrogio, L | 1 |
| Volpi, C | 1 |
| Grohmann, U | 1 |
| Sundaram, G | 2 |
| Lim, CK | 2 |
| Brew, BJ | 2 |
| Lemos, H | 1 |
| Mohamed, E | 1 |
| Ou, R | 1 |
| McCardle, C | 1 |
| Zheng, X | 1 |
| McGuire, K | 1 |
| Homer, NZM | 1 |
| Mole, DJ | 1 |
| Huang, L | 1 |
| Mellor, AL | 1 |
| Zarzecki, MS | 1 |
| Cattelan Souza, L | 1 |
| Giacomeli, R | 1 |
| Silva, MRP | 1 |
| Prigol, M | 1 |
| Boeira, SP | 1 |
| Jesse, CR | 1 |
| Fakan, B | 1 |
| Szalardy, L | 1 |
| Vecsei, L | 2 |
| Jones, SP | 1 |
| Adams, S | 1 |
| Sakurai, K | 1 |
| Zou, JP | 1 |
| Tschetter, JR | 1 |
| Ward, JM | 1 |
| Shearer, GM | 1 |
| Kwidzinski, E | 1 |
| Bechmann, I | 1 |
| Rajda, C | 1 |
| Bergquist, J | 1 |
| Chiarugi, A | 1 |
| Cozzi, A | 1 |
| Ballerini, C | 1 |
| Massacesi, L | 1 |
| Moroni, F | 1 |
3 reviews available for kynurenine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Immun | 2019 |
IDO expression in the brain: a double-edged sword.
Topics: Animals; Brain; Candidiasis; Cytomegalovirus Infections; Encephalomyelitis, Autoimmune, Experimental | 2007 |
Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.
Topics: Animals; Antioxidants; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Humans; Kynur | 2007 |
8 other studies available for kynurenine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway.
Topics: Animals; Biological Factors; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Hu | 2022 |
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.
Topics: Allosteric Regulation; Allosteric Site; Animals; Biocatalysis; Disease Models, Animal; Encephalomyel | 2020 |
Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Kynurenine; Mice; Signal | 2020 |
Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Antigen-Presenting Cells; Autoimmunity; B7-H1 Antigen; Chromatography, Liquid; Disease Mode | 2020 |
Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Topics: Animals; Body Weight; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Fem | 2020 |
Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Line, Transformed; Encephalomyelitis, Autoimmune, E | 2014 |
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Cell Division; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyel | 2002 |
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Topics: Animals; Astrocytes; Brain; Cytoplasmic Granules; Disease Models, Animal; Encephalomyelitis, Autoimm | 2001 |